Protagonist Therapeutics, Inc Increase (Decrease) in Accounts Payable
Protagonist Therapeutics, Inc (PTGX) reported Increase (Decrease) in Accounts Payable of $696.00 thousand for the 3-month period ending 2019-03-31, per its 10-Q filed 2019-05-08.
Discontinued › Cash Flow › Operating Activities
us-gaap:IncreaseDecreaseInAccountsPayable · last filed 2019-05-08
- Protagonist Therapeutics, Inc increase (decrease) in accounts payable for the quarter ending 2019-03-31 was $696.00K, a 3214.29% increase year-over-year.
- Protagonist Therapeutics, Inc increase (decrease) in accounts payable for the quarter ending 2018-12-31 was $813.00K.
- Protagonist Therapeutics, Inc increase (decrease) in accounts payable for the quarter ending 2018-09-30 was $2.60M.
- Protagonist Therapeutics, Inc increase (decrease) in accounts payable for the quarter ending 2018-06-30 was $993.00K, a 37.11% decline year-over-year.
- Protagonist Therapeutics, Inc increase (decrease) in accounts payable for fiscal 2018 was $4.43M, a 4768.13% increase from fiscal 2017.
- Protagonist Therapeutics, Inc increase (decrease) in accounts payable for fiscal 2017 was $91.00K.
- Protagonist Therapeutics, Inc increase (decrease) in accounts payable for fiscal 2016 was -$115.00K, a 112.81% decline from fiscal 2015.
- Protagonist Therapeutics, Inc increase (decrease) in accounts payable for fiscal 2015 was $898.00K, a 401.68% increase from fiscal 2014.
| Period end | Increase (Decrease) in Accounts Payable 3 month | Increase (Decrease) in Accounts Payable 6 month | Increase (Decrease) in Accounts Payable 9 month | Increase (Decrease) in Accounts Payable 12 month |
|---|---|---|---|---|
| 2019-03-31 | $696.00K 10-Q · filed 2019-05-08 | $1.51M derived: sum of 2 quarters · filed 2019-05-08 | $4.11M derived: sum of 3 quarters · filed 2019-05-08 | $5.11M derived: sum of 4 quarters · filed 2019-05-08 |
| 2018-12-31 | $813.00K derived: 10-K 12 month − 10-Q 9 month · filed 2019-03-12 | $3.42M derived: sum of 2 quarters · filed 2019-03-12 | $4.41M derived: sum of 3 quarters · filed 2019-03-12 | $4.43M 10-K · filed 2019-03-12 |
| 2018-09-30 | $2.60M derived: 10-Q 9 month − 10-Q 6 month · filed 2018-11-06 | $3.60M derived: sum of 2 quarters · filed 2018-11-06 | $3.62M 10-Q · filed 2018-11-06 | $2.61M derived: sum of 4 quarters · filed 2019-05-08 |
| 2018-06-30 | $993.00K derived: 10-Q 6 month − 10-Q 3 month · filed 2018-08-07 | $1.01M 10-Q · filed 2018-08-07 | $9.00K derived: sum of 3 quarters · filed 2019-05-08 | -$323.00K derived: sum of 4 quarters · filed 2019-05-08 |
| 2018-03-31 | $21.00K 10-Q · filed 2019-05-08 | -$984.00K derived: sum of 2 quarters · filed 2019-05-08 | -$1.32M derived: sum of 3 quarters · filed 2019-05-08 | $263.00K derived: sum of 4 quarters · filed 2019-05-08 |
| 2017-12-31 | -$1.00M derived: 10-K 12 month − 10-Q 9 month · filed 2019-03-12 | -$1.34M derived: sum of 2 quarters · filed 2019-03-12 | $242.00K derived: sum of 3 quarters · filed 2019-03-12 | $91.00K 10-K · filed 2019-03-12 |
| 2017-09-30 | -$332.00K derived: 10-Q 9 month − 10-Q 6 month · filed 2018-11-06 | $1.25M derived: sum of 2 quarters · filed 2018-11-06 | $1.10M 10-Q · filed 2018-11-06 | $824.00K derived: sum of 4 quarters · filed 2019-03-12 |
| 2017-06-30 | $1.58M derived: 10-Q 6 month − 10-Q 3 month · filed 2018-08-07 | $1.43M 10-Q · filed 2018-08-07 | $1.16M derived: sum of 3 quarters · filed 2019-03-12 | $1.23M derived: sum of 4 quarters · filed 2019-03-12 |
| 2017-03-31 | -$151.00K 10-Q · filed 2018-05-09 | -$423.00K derived: sum of 2 quarters · filed 2019-03-12 | -$351.00K derived: sum of 3 quarters · filed 2019-03-12 | -$859.00K derived: sum of 4 quarters · filed 2019-03-12 |
| 2016-12-31 | -$272.00K derived: 10-K 12 month − 10-Q 9 month · filed 2019-03-12 | -$200.00K derived: sum of 2 quarters · filed 2019-03-12 | -$708.00K derived: sum of 3 quarters · filed 2019-03-12 | -$115.00K 10-K · filed 2019-03-12 |
| 2016-09-30 | $72.00K derived: 10-Q 9 month − 10-Q 6 month · filed 2017-11-07 | -$436.00K derived: sum of 2 quarters · filed 2017-11-07 | $157.00K 10-Q · filed 2017-11-07 | $624.00K derived: sum of 4 quarters · filed 2018-03-07 |
| 2016-06-30 | -$508.00K derived: 10-Q 6 month − 10-Q 3 month · filed 2017-08-08 | $85.00K 10-Q · filed 2017-08-08 | $552.00K derived: sum of 3 quarters · filed 2018-03-07 | $823.00K derived: sum of 4 quarters · filed 2018-03-07 |
| 2016-03-31 | $593.00K 10-Q · filed 2017-05-10 | $1.06M derived: sum of 2 quarters · filed 2018-03-07 | $1.33M derived: sum of 3 quarters · filed 2018-03-07 | |
| 2015-12-31 | $467.00K derived: 10-K 12 month − 10-Q 9 month · filed 2018-03-07 | $738.00K derived: sum of 2 quarters · filed 2018-03-07 | $898.00K 10-K · filed 2018-03-07 | |
| 2015-09-30 | $271.00K derived: 10-Q 9 month − 10-Q 6 month · filed 2016-11-14 | $431.00K 10-Q · filed 2016-11-14 | ||
| 2015-06-30 | $160.00K 10-Q · filed 2016-09-15 | |||
| 2014-12-31 | $179.00K 10-K · filed 2017-03-07 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| TG THERAPEUTICS, INC. (TGTX) | United States | $8.805B | 19.05 |
| CYTOKINETICS INC (CYTK) | United States | $9.130B | -11.86 |
| ARROWHEAD PHARMACEUTICALS, INC. (ARWR) | United States | $9.331B | -42.28 |
| Praxis Precision Medicines, Inc. (PRAX) | United States | $7.884B | -27.60 |
| Structure Therapeutics Inc. (GPCR) | United States | $7.710B | -53.41 |
| Spyre Therapeutics, Inc. (SYRE) | United States | $7.685B | -43.69 |
| Axsome Therapeutics, Inc. (AXSM) | United States | $10.274B | -66.82 |
| IONIS PHARMACEUTICALS INC (IONS) | United States | $7.277B | -23.25 |
| Alkermes plc. (ALKS) | $6.844B | 132.74 | |
| RHYTHM PHARMACEUTICALS, INC. (RYTM) | United States | $6.771B | -37.20 |